Drugs / Suvecaltamide

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05642442 Dec 2022 → Oct 2024 Parkinson disease, movement disorder Jazz Pharmaceuticals Completed No outcome recorded
Phase 2 NCT05122650 Dec 2021 → May 2024 essential tremor Jazz Pharmaceuticals Completed No outcome recorded
Phase 2 NCT03436953 Dec 2019 → Sep 2020 Parkinson disease, movement disorder Jazz Pharmaceuticals Withdrawn No outcome recorded
Phase 2 NCT03406702 Feb 2018 → Mar 2019 epilepsy Jazz Pharmaceuticals Completed No outcome recorded
Phase 2 NCT03101241 Aug 2017 → Jul 2018 essential tremor Jazz Pharmaceuticals Completed No outcome recorded
Phase 2 NCT00827918 Mar 2009 → Apr 2010 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Suvecaltamide ClinicalTrials.gov intervention name — accepted as the source's own label NCT05642442
Known as CX-8998 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03406702
2

NCT03436953

NCT03101241

Known as CX-8998 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1684950
Known as JZP-385 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1684950
Known as JZP385 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05122650
Known as MK-8998 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00827918
Known as MK-8998 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1684950
Known as SUVECALTAMIDE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1684950
Action Inhibit “T-type calcium channel antagonist MK-8998” PMID 23532746 Mar 2013
Modality Small molecule CHEMBL1684950
Route Oral “administered orally (PO)” NCT05122650